This fund is the strategic corporate venture arm of the Swiss biopharmaceutical company, Debiopharm. With a fund size of $150 million, it invests in start-ups powering pharma R&D transformation and cancer care innovation, providing early seed (<$1 million) and series A ($3-5 million) funding.
